- Home
- PLX vs DMF Comparison
PLX vs DMF Comparison
Compare PLX & DMF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLX
- DMF
- Stock Information
- Founded
- PLX 1993
- DMF 1988
- Country
- PLX Israel
- DMF United States
- Employees
- PLX N/A
- DMF N/A
- Industry
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- DMF Finance/Investors Services
- Sector
- PLX Health Care
- DMF Finance
- Exchange
- PLX Nasdaq
- DMF Nasdaq
- Market Cap
- PLX 160.2M
- DMF 149.8M
- IPO Year
- PLX 1998
- DMF N/A
- Fundamental
- Price
- PLX $2.33
- DMF $7.20
- Analyst Decision
- PLX
- DMF
- Analyst Count
- PLX 0
- DMF 0
- Target Price
- PLX N/A
- DMF N/A
- AVG Volume (30 Days)
- PLX 553.9K
- DMF 60.7K
- Earning Date
- PLX 03-13-2025
- DMF 01-01-0001
- Dividend Yield
- PLX N/A
- DMF 2.66%
- EPS Growth
- PLX N/A
- DMF N/A
- EPS
- PLX N/A
- DMF 0.15
- Revenue
- PLX $45,667,000.00
- DMF N/A
- Revenue This Year
- PLX N/A
- DMF N/A
- Revenue Next Year
- PLX $90.00
- DMF N/A
- P/E Ratio
- PLX N/A
- DMF $45.13
- Revenue Growth
- PLX N/A
- DMF N/A
- 52 Week Low
- PLX $0.82
- DMF $5.37
- 52 Week High
- PLX $2.36
- DMF $6.79
- Technical
- Relative Strength Index (RSI)
- PLX 78.72
- DMF 54.31
- Support Level
- PLX $2.11
- DMF $7.07
- Resistance Level
- PLX $2.36
- DMF $7.18
- Average True Range (ATR)
- PLX 0.12
- DMF 0.08
- MACD
- PLX 0.00
- DMF 0.02
- Stochastic Oscillator
- PLX 94.23
- DMF 90.38
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
About DMF BNY Mellon Municipal Income Inc.
BNY Mellon Municipal Income, Inc. is a non-diversified closed-end management investment company. Its investment objective is to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital. The fund invests in municipal obligations that are rated investment grade and have maturities of less than one year. The company targets to invest in the sector such as education, pre-refunded muni, utility, transportation, healthcare, special tax, state/territory general obligations, industry revenue, and pollution control.